Compare Amgen, Inc. (AMGN) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Snap On Incorporated — how do they compare? Amgen, Inc. trades at $417.84 (market cap $224.14B), while Snap On Incorporated trades at $408.62 (market cap $21.30B). The key difference: Amgen, Inc. is far larger — about 10.5× Snap On Incorporated's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | SNA | |
|---|---|---|
Market Cap | $224.14B | $21.30B |
Sector | Health | Technology |
52-Week High | $417.20 | $419.31 |
52-Week Low | $271.18 | $321.38 |
Enterprise Value | $267.45B | $20.93B |
Dividend Yield | 2.43% | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Snap-on (SNA) trades at $407.04, down 0.99% today, with a bullish technical signal from moving averages and support near $406. The company reported strong Q2 2026 earnings of $4.96 per share, beating estimates, with organic sales growth of 3% and a net income margin of 19.6%. Recent acquisitions like Diesel Laptops for $100 million aim to expand its diagnostics reach.
The outlook remains positive with a consensus price target of $455.33, implying 12% upside, supported by robust cash flow and dividend payments. Key risks include integration costs from acquisitions and premium valuation multiples, while softer OEM demand and economic sensitivity could pressure near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
